Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 310
Selected: 0
NCT IDTitle
NCT03329365Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
NCT00380159Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
NCT04021082CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT05389449A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT03310021A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
NCT04557735Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT07413679Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
NCT01770951A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05396742Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
NCT03369236A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
NCT03406507A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
NCT02226146Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
NCT04920370Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
NCT04725812Complement Regulation to Undo Systemic Harm in Preeclampsia
NCT01522170aHUS Observational Long Term Follow-Up
NCT00312039Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
NCT05751642Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
NCT01454986Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
NCT02245867Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
NCT04543591Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
NCT01700179Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
NCT01919346Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation
NCT06578949Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04564339Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT04573309Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
NCT00122304Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
NCT02345421A Study to Identify and Characterize LAL-D Patients in High-risk Populations
NCT01994382Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
NCT05644561Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
NCT01180790Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
NCT03384186A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
NCT04802083COVID-19 Soliris Expanded Access Protocol
NCT01412047Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
NCT01528917An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
NCT04622046A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
NCT05886244Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
NCT00838513Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05254613A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants
NCT01193348An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
NCT04504825A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
NCT07413250Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
NCT00648739Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
NCT01192399Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT04560816A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
NCT03766347Pediatric NMOSD Observational Study
NCT01758432Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)
NCT04469465Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
NCT02987504Study of Samalizumab in Patients With Advanced Cancer
NCT05981092A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)